Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hal Allergy, an European manufacturer of allergy vaccines has enrolled the first patient in its Phase II dose range finding study to test the efficacy and safety of Purethal Mites in patients with allergic rhinitis/rhinoconjunctivitis.
Subscribe to our email newsletter
The study had been commenced in September 2011 in five European countries.
Purethal Mites is a modified aluminum hydroxide-adsorbed extract of house dust mites for subcutaneous use, to treat severe allergic respiratory diseases.
Hal Allergy CEO Harry Flore said the commencement of the trial marks a significant step in the company’s clinical development plan.
"It also stresses our commitment to meet today’s requirements for gaining registration for specific immunotherapy products," Flore added.